Research Topics
| T H J GoodshipSummaryAffiliation: University of Newcastle Country: UK Publications
| Collaborators
|
Detail Information
Publications
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomyR Thomas Jagoe
Department of Medicine, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
Clin Sci (Lond) 102:353-61. 2002....
Disordered calcium crystal handling in antisense CLC-5-treated collecting duct cellsJohn A Sayer
Department of Medicine, University of Newcastle upon Tyne, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
Biochem Biophys Res Commun 300:305-10. 2003..We conclude that expression of CLC-5 in mIMCD-3 cells allows acidification of endosomes and endocytosis, and that disruption of CLC-5 expression causes abnormal crystal agglomeration...
Atypical HUS and complement dysregulationTimothy H J Goodship
J Am Soc Nephrol 17:1775-6. 2006
Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMDT H J Goodship
Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
Kidney Int 70:12-3. 2006..The report of Licht et al. of a mutation in the complement-regulatory N-terminal region of Factor H in MPGN II provides additional insight into the pathogenesis of this condition...
Factor H autoantibodies in membranoproliferative glomerulonephritisTimothy H J Goodship
Institutes of Cellular Medicine and Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
Mol Immunol 52:200-6. 2012..Antibody depleting therapy may have a role in such patients and we suggest that screening for factor H autoantibodies should be undertaken in all patients with MPGN...
Mutations in CD46, a complement regulatory protein, predispose to atypical HUSTimothy H J Goodship
Institute of Human Genetics, University of Newcastle upon Tyne, NE 13BZ, UK
Trends Mol Med 10:226-31. 2004..In the other two, a substitution (S206P) resulted in cell-surface expression but inefficient inactivation of surface-bound C3b. These findings provide further evidence that complement dysregulation predisposes to the development of HUS...
Long-term follow-up of patients presenting to adult nephrologists with chronic pyelonephritis and 'normal' renal functionT H Goodship
Department of Nephrology, School of Clinical Medical Sciences, and Department of Radiology, University of Newcastle upon Tyne
QJM 93:799-803. 2000..Most could be referred back to their general practitioner for long-term follow-up...
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeIain Moore
Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom
Blood 115:379-87. 2010..In 5 patients mutations were identified: 1 in CFH, 1 in CFI, 1 in CD46, and 2 in C3. The latter observation emphasizes that multiple concurrent factors may be necessary in individual patients for disease manifestation...
Does complement factor B have a role in the pathogenesis of atypical HUS?David Kavanagh
Washington University School of Medicine, Campus Box 8045, St Louis, MO 63110, USA
Mol Immunol 43:856-9. 2006..In conclusion, in this small series of aHUS patients we found no evidence that fB has a major role in the pathogenesis of aHUS...
Atypical hemolytic uremic syndromeDavid Kavanagh
The Institute of Human Genetics, International Centre for Life, Newcastle University, Newcastle upon Tyne, UK
Curr Opin Hematol 17:432-8. 2010..Many different predisposing genetic factors resulting in complement overactivation have been described in aHUS. Additionally, autoantibodies against complement regulatory proteins have been reported...
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndromeAnna Richards
Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle NE1 4LP, United Kingdom
Proc Natl Acad Sci U S A 100:12966-71. 2003..This study presents further evidence that complement dysregulation predisposes to development of thrombotic microangiopathy and that screening patients for such defects could provide informed treatment strategies...
Complement polymorphisms: geographical distribution and relevance to diseaseL Ermini
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Immunobiology 217:265-71. 2012..The analysis of genetic variation in complement genes is a promising tool to unravel mechanisms of host-pathogen interaction and can provide new insights into the evolution of the human immune system...
Is complement factor H a susceptibility factor for IgA nephropathy?Matthew Edey
Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK
Mol Immunol 46:1405-8. 2009..All the patients had a normal serum factor H concentration. In this small cohort of IgA nephropathy patients we have not found evidence to support the hypothesis that factor H is a major susceptibility factor for the disease...
Atypical haemolytic uraemic syndrome associated with a hybrid complement geneJulian P Venables
Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
PLoS Med 3:e431. 2006..In this study we tested the hypothesis that nonallelic homologous recombination between low-copy repeats in the RCA cluster could result in the formation of a hybrid CFH/CFHL1 gene that predisposes to the development of aHUS...
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndromeDavid Kavanagh
Institute of Human Genetics, University of Newcastle upon Tyne, Tyne and Wear NE1 3BZ, UK
J Am Soc Nephrol 16:2150-5. 2005..As with CFH- and MCP-associated HUS, there was incomplete penetrance in the family of one of the affected individuals. This study provides further evidence that atypical HUS is a disease of complement dysregulation...
Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illnessMatthew M Edey
Department of Nephrology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Am J Kidney Dis 51:487-90. 2008..We recommend consideration of complement gene mutations in any patient with HUS after a diarrheal episode in which there are unusual features...
Membrane cofactor protein and factor I: mutations and transplantationDavid Kavanagh
Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
Semin Thromb Hemost 32:155-9. 2006..Combined liver/kidney transplantation for patients known to have a CFH mutation has not been successful to date. There is optimism that in the future, targeted complement inhibitors will be of major therapeutic benefit in this condition...
The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraAnna Richards
The Institute of Human Genetics and School of Clinical Medical Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne NE1 4LP, UK
Curr Opin Nephrol Hypertens 11:431-5. 2002..These recent advances will lead to logical, targetted changes in the management of these conditions...
Whole-genome linkage and association scan in primary, nonsyndromic vesicoureteric refluxHeather J Cordell
Institute of Human Genetics, Newcastle University, International Centre for Life, Newcastle upon Tyne, NE1 3BZ, UK
J Am Soc Nephrol 21:113-23. 2010..The results of this study, which is the largest to date investigating the genetics of reflux, suggest that major loci may not exist for this common renal tract malformation within European populations...
Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donorRosemary L Donne
School of Clinical Medical Sciences, University of Newcastle upon Tyne, England
Am J Kidney Dis 40:E22. 2002..Neither family has a factor H mutation. This report underlines the risk of disease recurrence in recipients associated with live-related renal transplantation in HUS and also suggests that the donors may be at risk...
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndromePeter F Zipfel
Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute, Jena, Germany
PLoS Genet 3:e41. 2007..The identification of CFHR1/CFHR3 deficiency in aHUS patients may lead to the design of new diagnostic approaches, such as enhanced testing for these genes...
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activityAnna M Blom
Lund University, Department of Laboratory Medicine, Malmo University Hospital, Malmo, Sweden
J Immunol 180:6385-91. 2008..Three of the patients carry also mutations in membrane cofactor protein and factor H strengthening the hypothesis that individuals may carry multiple susceptibility factors with an additive effect on the risk of developing aHUS...
Complement factor H and the hemolytic uremic syndromeJohn P Atkinson
Division of Rheumatology, Washington University School of Medicine, St Louis, MO 63110, USA
J Exp Med 204:1245-8. 2007..A mouse model of HUS designed to mirror human mutations in FH has now been developed, providing new understanding of the molecular pathogenesis of complement-related endothelial disorders...
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndromeM Kathryn Liszewski
Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8045, St Louis, MO 63110, USA
Mol Immunol 44:1559-68. 2007..Our results add new information relative to the necessity for appropriate expression levels of MCP and further implicate the alternative pathway in disease processes such as aHUS...
Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutationsAnne Laure Lapeyraque
Department of Pediatrics, Division of Nephrology, CHU Sainte Justine, Montreal, QC, Canada
Pediatr Nephrol 23:1363-6. 2008..Long-term tolerance and efficacy of such intensive plasma therapy are still unknown. Reported secondary failure of plasma therapy in factor H deficiency warrants the search for alternative therapeutic approaches...
Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding siteStephen J Perkins
Department of Biochemistry and Molecular Biology, Royal Free and University College Medical School, University College London, Rowland Hill Street, London, NW3 2PF, UK
J Mol Biol 316:217-24. 2002..As the remaining FH substitutions could also be correlated with their proximity to conserved basic residues, haemolytic uraemic syndrome may result from a failure of FH to interact with polyanions at cell surfaces in the kidney...
An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutationsRebecca E Saunders
Department of Biochemistry and Molecular Biology, Royal Free and University College Medical School, University College London, London, United Kingdom
Hum Mutat 27:21-30. 2006..This FH web database will facilitate the interpretation of new mutations and polymorphisms when these are identified in patients, and it will clarify the functional role of FH...
Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneitySongshan Jiang
Epithelial Biology Unit, Ronald O Perelman Department of Dermatology, Kaplan Comprehensive Cancer Center, New York University Medical School, New York, New York, USA
Kidney Int 66:10-9. 2004..Recent studies indicate that genetic ablation of mouse uroplakin (UP) III gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and hydronephrosis...
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndromeCelia J Fang
Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
Blood 111:624-32. 2008..Both the R69W and A304V MCP mutations were deficient in their ability to control the alternative pathway of complement activation on a cell surface, illustrating the importance of modeling transmembrane proteins in situ...
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic backgroundElena Bresin
Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Via Camozzi, 3, 24020 RANICA Bergamo, Italy
Clin J Am Soc Nephrol 1:88-99. 2006..It is debatable whether a kidney transplant should be recommended for patients with CFH or IF mutation. Reasonably, patients with an MCP mutation can undergo a kidney transplant without risk for recurrence...
Atypical relapse of hemolytic uremic syndrome after transplantationKarolien H Olie
Pediatric Nephrology Unit, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands
Pediatr Nephrol 19:1173-6. 2004..This patient demonstrates that HUS can recur in a kidney transplant without the diagnostic hematological features and emphasizes the need for early transplant biopsy in such patients showing a decline in transplant function...
Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovirKarolien H Olie
Paediatric Nephrology Unit, Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands
Am J Kidney Dis 45:e12-5. 2005..The feasibility of kidney transplantation in case of atypical HUS related to factor H mutation using continuous prophylactic PE intensified during relapses should be confirmed in prospective studies...
Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatmentJean Claude Davin
Emma Children s Hospital, Department of Pediatric Nephrology and Pathology, Academic Medical Centre, Amsterdam, The Netherlands
Am J Kidney Dis 47:e27-30. 2006..73 m2 [1.98 mL/s/1.73 m2]) on maintenance PE therapy. In conclusion, the response to treatment of these monozygotic twins suggests that long-term PE may have benefits over plasma infusion alone...
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndromeStefan Heinen
Department for Infection Biology, Hans Knoell Institute for Natural Products Research, Jena, Germany
Hum Mutat 27:292-3. 2006..We, therefore, provide conclusive evidence that gene conversion is responsible for functionally significant CFH mutations in aHUS...
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndromeAnna Richards
Department of Medicine, Division of Rheumatology, Washington University School of Medicine, Campus Box 8045, 660 South Euclid Avenue, St Louis, MO 63110, USA
Mol Immunol 44:111-22. 2007..This highlights the importance of defining and characterizing the underlying genetic defects in patients with aHUS...
Atypical haemolytic uraemic syndromeDavid Kavanagh
Washington University School of Medicine, St Louis, MO 63110, USA
Br Med Bull 77:5-22. 2006..Discovery of these mutations has revealed important genotype-phenotype correlations. MCP-HUS has a better prognosis and a better outcome after transplantation than either CFH-HUS or IF-HUS...
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural modelsRebecca E Saunders
Department of Biochemistry and Molecular Biology, Royal Free and University College Medical School, University College London, London, United Kingdom
Hum Mutat 28:222-34. 2007..The database emphasizes the causative role of the alternative pathway of complement in disease and provides a repository of knowledge to assist future diagnosis and novel therapeutic approaches...
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndromeDavid Kavanagh
Division of Rheumatology, Washington University School of Medicine, St Louis, MO 63110, USA
Mol Immunol 45:95-105. 2008..The excessive complement activation for a given degree of damage may result in generation of a procoagulant state and aHUS...
Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1beta mutationsCoralie Bingham
Department of Vascular Medicine and Diabetes Research, School of Postgraduate Medicine and Health Sciences, University of Exeter, Devon, United Kingdom
Kidney Int 61:1243-51. 2002..Renal and uterine abnormalities have not been described in families without early-onset diabetes...
